MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Large-Bore Access Site Management
State-of-the-art closure techniques for large-bore access.
By Amir Kaki, MD, and M. Chadi Alraies, MD
Percutaneous Transaxillary Access
Tips and tricks for a successful and safe alternate large-bore access.
By Pooja M. Swamy, MD; Rajiv Tayal, MD, MPH, FSCAI; and Amir Kaki, MD, FACC, FSCAI
Abiomed’s Pivotal Impella ECP Study Expands Enrollment
April 24, 2023—Abiomed, part of Johnson & Johnson MedTech, announced the expansion of enrollment in the Impella ECP study.
First Patients Treated in Feasibility Study of Abiomed’s 9-F Impella ECP Expandable Percutaneous Heart Pump
October 28, 2020—Abiomed announced that the first two patients have been treated with the Impella ECP expandable percutaneous heart pump, which is being studied in an FDA early feasibility study.
CathWorks FFRangio System’s ALL-RISE Trial Completes Enrollment
January 6, 2025—CathWorks recently announced the completion of enrollment for the ALL-RISE randomized controlled trial, evaluating the clinical and economic benefits of the CathWorks FFRangio system in diagnosing and treating coronary artery disease.
FastWave Receives IRB Approval for Feasibility Study of Sola Laser IVL System
May 7, 2025—FastWave Medical announced it has received institutional review board (IRB) approval to commence a coronary feasibility study using the company’s Sola laser intravascular lithotripsy (L-IVL) system.
FastWave Announces Medical Advisor Appointments and Pipeline Update
March 6, 2024—FastWave Medical Inc., a device company focused the treatment of calcified cardiovascular disease through intravascular lithotripsy (IVL), recently announced the appointments of eight medical advisors.
First Patient Enrolled in CathWorks ALL-RISE Study Evaluating FFRangio System
June 28, 2023—CathWorks announced that the first patient has been enrolled in the ALL-RISE study sponsored by the company.
Vantis Vascular’s CrossFast System Used in First Commercial Cases
January 23, 2025—Vantis Vascular, Inc. announced the first commercial use of its CrossFast integrated microcatheter advanced delivery system in a series of 10 complex high-risk coronary interventional procedures (CHiP).
Abiomed Begins PROTECT IV RCT of Impella in High-Risk PCI
April 15, 2021—Abiomed announced that the first patient has been enrolled in the PROTECT IV study of the company’s Impella device.
Abiomed’s Impella ECP Pivotal Trial Enrolls First Patients
December 21, 2022—Abiomed announced the commencement of the pivotal Impella ECP Study after receiving FDA approval for investigational use of the version of the Impella ECP expandable percutaneous heart pump that will be evaluated in the pivotal trial.
Abiomed’s Impella ECP Pivotal Study Investigates Safety, Efficacy for Use in High-Risk PCI
October 28, 2024—Abiomed, part of Johnson & Johnson MedTech, announced the results from the company’s pivotal trial of patients supported with the company’s Impella ECP transvalvular axial flow pump, which features compressible pump architecture.
FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients With Right Heart Failure
June 1, 2020—Abiomed announced that the FDA has issued an emergency use authorization (EUA) for the company’s Impella RP to include patients with COVID-19–related right heart failure or decompensation, including pulmonary embolism (PE).
Learn the Technique
By Azeem Latib, MD
Contemporary Catheter-Based Structural Heart and Vascular Access Closure Options
By Rahul Sharma, MD, FACP, FACC, FSCAI, and Nicolas M. Van Mieghem, MD, PhD, FACC, FESC
Sponsored by ACIST
Making the Case for CI-AKI Prevention With the ACIST CVi™ Contrast Delivery System
How can this technology benefit my practice and my cath lab?
With Sandeep Krishnan, MD, FACC, FSCAI
Cardiovascular Magnetic Resonance
An analysis of this imaging modality for structural heart disease interventions.
By Akhil Narang, MD, and Amit Pursnani, MD
CVi Contrast Delivery System
Acist Medical Systems, Inc.
